针对驱动基因阳性非小细胞肺癌的免疫疗法的进展:叙述性综述
Fangfei Qian1, Runbo Zhong1, Hua Zhong1
1Department of Respiratory and Critical Care Medicine, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Translational lung cancer research
|August 13, 2025
概括
免疫疗法对驱动基因阳性非小细胞肺癌 (NSCLC) 有希望,但疗效因基因突变而异. 组合疗法是克服耐药性和个性化治疗高级NSCLC的关键.
科学领域:
- 在瘤学瘤学.
- 免疫学 免疫学 免疫学
- 遗传学 遗传学是一种遗传学.
背景情况:
- 免疫疗法是驱动基因阴性高级非小细胞肺癌 (NSCLC) 的标准.
- 免疫疗法在驱动基因阳性NSCLC中的有效性正在研究中.
- 本综述探讨了驱动基因阳性NSCLC免疫疗法的最新进展和挑战.
研究的目的:
- 系统地审查和批判性地分析最近关于驱动基因阳性NSCLC免疫治疗的文献.
- 提高对免疫治疗在驱动基因阳性NSCLC中的作用的理解.
- 探索克服驱动基因阳性NSCLC中耐药性的策略.
主要方法:
- 在PubMed,科学网,Scopus和谷歌学者的系统文献搜索.
- 关键词包括"免疫疗法"",非小细胞肺癌"和"驱动基因阳性".
- 双重独立选和团队会议确保了全面的解释.
主要成果:
- 驱动基因突变显著影响瘤免疫微环境和免疫治疗反应.
- 对于EGFR突变的NSCLC,向治疗是第一线治疗;免疫疗法组合应考虑在耐药性方面.
- 免疫疗法加化学疗法是KRAS突变NSCLC的首选;抗体-药物合物加免疫疗法可能适合HER2-改变的NSCLC.
- 关于不常见的驱动器改变和新辅助免疫疗法加化疗的研究正在进行中.
结论:
- 优化生物标志物和组合疗法对于个性化治疗策略至关重要.
- 需要进一步的研究来解决有关驱动基因阳性NSCLC免疫治疗的剩余问题.
- 个性化方法对于克服驱动基因阳性NSCLC的耐药性至关重要.
相关概念视频
Tumor Immunotherapy
660
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
660
Gene Therapy
25.9K
Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be...
25.9K
Cancer Vaccines
509
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
509
Targeted Cancer Therapies
7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.8K
Combination Therapies and Personalized Medicine
5.1K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.1K
Treatment Resistant Cancers
3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K


